Drug discovery chemistry startup Warp Sciences Inc. launched today with $215 million in new funding, six months after co-founder and Chief Executive Kevin Weil left his job running science initiatives at OpenAI Group PBC. Warp is building a chemistry contract research organization in the U.S. to supply biotech and pharmaceutical companies with the molecules their […] The post Ex-OpenAI science chief Kevin Weil launches Warp Sciences with $215M for drug chemistry appeared first on SiliconANGLE.